Navigation Links
New therapeutic target for treatment of multiple sclerosis
Date:1/22/2008

Montreal, January 22, 2007 An international research team, led by a scientist from the Centre hospitalier de lUniversit de Montral (CHUM), has identified new therapeutic targets for the treatment of multiple sclerosis (MS). In the February issue of Nature Immunology, the team provides fresh answers concerning the role of novel adhesion molecules in the pathogenesis of MS, a chronic autoimmune disease of the nervous system that affects approximately 55,000 young adults in Canada.

Conducted by Dr. Alexandre Prat, a CHUM neurologist and researcher and a professor at the Universit de Montrals Faculty of Medicine, the study included collaborators from McGill University (Dr. S. David), the Universit de Montral (Dr. N. Arbour), the National Research Council of Canada (Dr. D. Stanimirovic) and University of Zrich (Dr. B. Becher). The team found that the adhesion molecule dubbed ALCAM (Activated Leukocyte Cell Adhesion Molecule), or CD166, plays a major role in the migration of certain types of leukocytes to the brain.

The researchers believe that the molecule, which is expressed by the endothelial cells of the brain, constitutes a novel target to restrict migration of immune cells to the brain, thereby dampening neuroinflammation and decreasing the lesions characteristic of MS. Understanding the molecular mechanisms of brain inflammation is essential in the development of new treatments for MS.

Dr. Prat and his team clearly demonstrate that CD166/ALCAM is involved in the inflammatory process by priming the migration of leukocytes across the blood-brain barrier (BBB). The investigation combined the results of an in vitro human BBB model and an in vivo experimental autoimmune encephalomyelitis mouse model. Normally, a limited number of immune cells are able to cross the BBB and penetrate the central nervous system. In MS and other neuroinflammatory diseases, the increased permeability of the BBB is associated with an increase in the transmigration of some of these immune cells, which penetrate the central nervous system and cause the demyelinating lesions of MS. A previous study by Dr. Prats team published in October in Nature Medicine, proved that a certain type of leukocyte, the TH17 lymphocyte, produces two critical products, interleukins 17 and 22 (IL-17 and IL-22), which contribute to infiltrating the blood-brain barrier and causing inflammation of the central nervous system.

Blocking the migration of immune cells across the BBB has long been considered a promising therapeutic approach to autoimmune diseases of the central nervous system, said Dr. Prat. This study has given us new insight into the factors involved in the pathogenesis of immune reactions affecting the central nervous system and allowed us to identify potential targets to suppress neuroinflammatory processes.

An attractive therapeutic target

Pharmacological agents exist that reduce the transmigration of immune cells by specifically blocking leukocyte adhesion molecules, which significantly decrease the extent of CNS inflammation. However, they also impede the immune systems ability to provide protection against chronic viral infections of the central nervous system, such as progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system caused by the JC virus. Since ALCAM/CD166 blockade does not affect CD8+ T cell migration, whose main function is to destroy cells infected by viruses and neoplastic cells, the study results suggest that CNS immune protection against viruses would not be compromised by ALCAM blockade in vivo. ALCAM/CD166 could be considered as an attractive therapeutic target for multiple sclerosis.


'/>"/>

Contact: Nathalie Forgue
nathalie.forgue.chum@ssss.gouv.qc.ca
51-489-080-001-4342
University of Montreal
Source:Eurekalert

Related medicine news :

1. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
2. Transition Therapeutics Announces Appointment of Vice-President of Business Development
3. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
4. Transition Therapeutics Announces Milestone Payment from Elan
5. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
6. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
7. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
8. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
9. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
10. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
11. New therapeutic options for newly diagnosed multiple myeloma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology: